Reckitt Benckiser 1st Half Pretax Profit Fell Despite Price Growth; Backs Revenue Guidance
By Joe Hoppe
Reckitt Benckiser Group said Wednesday that pretax profit for the first half of the year slipped despite a rise in revenue, as volumes slipped and operating expenses rose, and backed its revenue growth expectations for the full year.
The consumer-goods company--which houses Dettol, Harpic and Durex among its brands--posted a pretax profit of 1.64 billion pounds ($2.12 billion) for the six months compared with a profit of GBP1.69 billion in the year-earlier period. Prices/mix was up 10.4%, while volumes fell 4.4%.
Adjusted operating profit rose to GBP1.77 billion, from GBP1.765 billion.
Reckitt backed guidance for 2023 revenue growth on a like-for-like basis in the range of 3% to 5%. It raised guidance for its adjusted operating margin to be slightly ahead of 2022 levels from prior guidance of it being flat, when excluding a one-off benefit related to U.S. nutrition.
Revenue rose to GBP7.45 billion from GBP6.89 billion the prior year. Meanwhile, revenue for the second quarter was GBP3.53 billion, compared with GBP3.46 billion for the second quarter a year before.
The board declared an interim dividend of 76.6 pence a share, up from 73 pence last year.
"Amidst a backdrop of challenging market conditions and uncertainty, the business has strong momentum, yet with an opportunity to further strengthen our execution, optimise our cost base, and deliver improved returns to shareholders," Chief Executive Officer Nicandro Durante said.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
July 26, 2023 02:41 ET (06:41 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth